| Literature DB >> 22272175 |
Hagen Schmal1, Alexander T Mehlhorn, Ingo H Pilz, David Dovi-Akue, Christina Kirchhoff, Norbert P Südkamp, Ulrike Gerlach, Christian Lohrmann, Philipp Niemeyer.
Abstract
INTRODUCTION: Although it is well known that BMP-2 and BMP-7 play significant roles in cartilage metabolism, data about intra-articular expression and localization of these proteins and their receptors in humans are rare.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22272175 PMCID: PMC3259605 DOI: 10.1100/2012/467892
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Specification of the used antibodies for immunohistology.
| Antibody | BMP-2 | BMP-7 | BMPR-1A | BMPR-1B | BMPR-2 |
|---|---|---|---|---|---|
| Specification | Mouse, monoclonal | Rabbit, polyclonal | Rabbit, polyclonal | Mouse, monoclonal | Rabbit, polyclonal |
| Dilution | 1 : 200 | 1 : 200 | 1 : 25 | 1 : 200 | 1 : 50 |
| Procedure for protein unmasking | Proteinase K (Dako REAL Proteinase K, Hamburg, Germany) | Proteinase K | Heat-induced antigen unmasking | Heat-induced antigen unmasking | Proteinase K (Dako REAL Proteinase K, Hamburg, Germany) |
| Manufacturer and product number | Abcam, ab6285, Cambridge, UK | Abcam, ab56023, Cambridge, UK | Lifespan Biosciences, LS-C4217, Seattle, USA | Abcam, ab78417, Cambridge, UK | Sigma, HPA017385, St. Louis, USA |
Figure 1Quantitation of BMP-2, BMP-7, and their receptors in cartilage and synovia.
Figure 2Immunostaining of cartilage, (a) BMPR-1A (summary score 6), (b) BMPR-1B (summary score 1), (c) BMPR-2 (summary score 1), (d) BMP-7 (summary score 6), (e) BMP-2 (summary score 4).
Figure 3Immunostaining of synovia, positive staining (arrows) is indicated by the red color mainly located around the nucleus of chondrocytes, (a) BMPR-1A (summary score 6), (b) BMPR-1B (summary score 1), (c) BMPR-2 (summary score 1), (d) BMP-7 (summary score 6), (e) BMP-2 (summary score 2).
Correlation matrix.
| Defect size | KOSS (MRI) | Henderson score | Kellgren-Lawrence score | Duration (months) | Krenn score | |
|---|---|---|---|---|---|---|
| Defect size | ||||||
|
| ||||||
| Corr. coefficient | 1.0000 |
| 0.1567 |
| 0.1478 | −0.2382 |
| Valid cases | 15 |
| 15 |
| 15 | 15 |
| Significance ( | 0.0000 | 0.0063* | 0.2886 | 0.0384* | 0.2995 | 0.1963 |
|
| ||||||
| KOSS (MRI) | ||||||
|
| ||||||
| Corr. coefficient |
| 1.0000 |
| 0.2468 |
| −0.1165 |
| Valid cases |
| 15 |
| 15 |
| 15 |
| Significance ( | 0.0063* | 0.0000 | 0.0075* | 0.1876 | 0.0062* | 0.3397 |
|
| ||||||
| Henderson score | ||||||
|
| ||||||
| Corr. coefficient | 0.1567 |
| 1.0000 | −0.2089 | 0.3768 |
|
| Valid cases | 15 |
| 15 | 15 | 15 |
|
| Significance ( | 0.2886 | 0.0075* | 0.0000 | 0.2274 | 0.0831 | 0.0421* |
|
| ||||||
| Kellgren-Lawrence score | ||||||
|
| ||||||
| Corr. coefficient |
| 0.2468 | −0.2089 | 1.0000 | −0.3197 | 0.0330 |
| Valid cases |
| 15 | 15 | 15 | 15 | 15 |
| Significance ( | 0.0384* | 0.1876 | 0.2274 | 0.0000 | 0.1227 | 0.4536 |
|
| ||||||
| Duration of symptoms (months) | ||||||
|
| ||||||
| Corr. coefficient | 0.1478 |
| 0.3768 | −0.3197 | 1.0000 | 0.1238 |
| Valid cases | 15 |
| 15 | 15 | 15 | 15 |
| Significance ( | 0.2995 | 0.0062* | 0.0831 | 0.1227 | 0.0000 | 0.3301 |
|
| ||||||
| Krenn score (synovitis) | ||||||
|
| ||||||
| Corr. coefficient | −0.2382 | −0.1165 |
| 0.0330 | 0.1238 | 1.0000 |
| Valid cases | 15 | 15 |
| 15 | 15 | 15 |
| Significance ( | 0.1963 | 0.3397 | 0.0421* | 0.4536 | 0.3301 | 0.0000 |
*P < 0.05, corr. coefficient: correlation coefficient (Spearman-Rho), Syn: synovia, C: cartilage.
Comparison between patients with different durations of complains (≤48 months n = 7, >48 months n = 8).
| Criterion | Duration of symptoms | Significance ( | |
|---|---|---|---|
| ≤48 months | >48 months | ||
| Age | 39.22 ± 12.39 | 27.78 ± 6.732 | 0.0638* |
| Gender (f/m) | 3/8 | 3/1 | 0.7552# |
| ICRS score | 3.43 ± 0.53 | 3.62 ± 0.52 | 0.4623* |
| Defect size | 3.68 ± 1.34 | 3.97 ± 1.67 | 0.4437* |
| KOSS (MRI) | 5.86 ± 1.57 | 8.25 ± 1.98 | 0.0202* |
| Henderson score | 2.00 ± 0.82 | 2.87 ± 1.36 | 0.1697* |
| Kellgren-Lawrence score | 1.00 ± 0.58 | 0.87 ± 0.83 | 0.7023* |
| Duration of symptoms (months) | 23.43 ± 16.36 | 76.50 ± 23.95 | 0.0010* |
| Krenn score | 2.00 ± 1.41 | 2.25 ± 1.03 | 0.5048* |
| BMP-2-Syn | 2.28 ± 1.89 | 2.37 ± 2.06 | 1.0000* |
| BMP-2-C | 2.43 ± 1.90 | 2.25 ± 1.58 | 0.9500* |
| BMPR-1A-Syn | 5.00 ± 1.00 | 4.75 ± 0.89 | 0.6171* |
| BMPR-1A-C | 2.57 ± 1.62 | 2.62 ± 2.37 | 0.9000* |
| Mankin score | 8.00 ± 2.00 | 7.375 ± 3.02 | 0.8590* |
| Pritzker score | 3.43 ± 0.79 | 3.62 ± 1.51 | 0.9497* |
*U-Test (Mann-Whitney), #Fisher exact test, f: female, m: male, Syn: synovia, C: cartilage.
Comparison between patients with different localizations of chondromalacia (retropatellar n = 6 or medial femoral condyle n = 8).
| Criterion | Medial femoral condyle | Retropatellar | Significance ( |
|---|---|---|---|
| Age | 30.73 ± 10.85 | 35.49 ± 12.64 | 0.6982* |
| Gender (f/m) | 2/3 | 3/5 | 0.9999# |
| ICRS score | 3.75 ± 0.46 | 3.17 ± 0.41 | 0.0374* |
| Defect size | 4.09 ± 1.79 | 3.29 ± 0.94 | 0.1882* |
| KOSS (MRI) | 8.12 ± 2.17 | 5.5 ± 0.87 | 0.0201* |
| Henderson score | 2.87 ± 1.36 | 2.00 ± 0.89 | 0.1826* |
| Kellgren-Lawrence score | 0.75 ± 0.89 | 1.00 ± 0.00 | 0.3838* |
| Duration of symptoms (months) | 65.25 ± 37.84 | 32.33 ± 21.55 | 0.0515* |
| Krenn score | 2.25 ± 1.28 | 2.00 ± 1.26 | 0.6836* |
| BMP-2-Syn | 2.62 ± 2.26 | 2.17 ± 1.60 | 0.9427* |
| BMP-2-C | 2.00 ± 1.19 | 2.33 ± 2.06 | 1.000* |
| BMPR-1A-Syn | 5.25 ± 0.89 | 4.50 ± 0.84 | 0.1279* |
| BMPR-1A-C | 2.50 ± 2.26 | 2.50 ± 1.76 | 0.8860* |
| Mankin score | 8.00 ± 3.34 | 7.67 ± 0.82 | 0.8943* |
| Pritzker score | 4.00 ± 1.41 | 3.17 ± 0.41 | 0.2810* |
*U-Test (Mann-Whitney), #Fisher exact test, f: female, m: male, Syn: synovia, C: cartilage.